We would love to hear your thoughts about our site and services, please take our survey here.
a little bit more.... an hour ago
Eli Lilly’s Covid-19 Antibody drug FDA EUA should reduce hospitalisations
Tue 10 Nov 2020 01:52:49 GMTAuthor: Eamonn Sheridan | Category: News
The further positive-sign coronavirus headline is here from earlier
Eli Lilly COVID-19 antibody granted approval for emergency use
Wall Street Journal have a little more up on this and its implications, in summary:
first treatment for people with earlier-stage Covid-19 who aren’t hospitalized
Eli Lilly’s antibody drug should be used for patients ages 12 and up with mild to moderate Covid-19, based on a study showing it helped improve symptoms and kept many patients out of the hospital
FDA authorized for patients at high risk of progressing to severe Covid-19
https://www.forexlive.com/news/!/eli-lillys-covid-19-antibody-drug-fda-eua-should-reduce-hospitalisations-20201110
How far down the line is Vlad with his research into Covid, we should be well ahead of this latest piece of news.......
By Philippa Roxby
Health reporter
Published11 hours ago
Related Topics
Coronavirus pandemic
Sars-CoV2 virus
IMAGE COPYRIGHTGETTY IMAGES
image captionThe many ways the body's immune system responds to Sars-CoV2 are still being discovered
Scientists have found evidence of immune cells responding to Covid-19 six months after people were infected.
In a study of 100 people with the virus, those with symptoms had a much higher T-cell reaction.
But it is still not clear whether this leads to better protection against re-infection.
The UK research team says the findings are "just one piece of the puzzle" on immunity and there is still a lot to learn.
The key question is whether being infected once with coronavirus can protect the body against being infected again and, if so, how long this immunity could last.
Scientists know that antibodies are made by the body from around 10 days after infection, but appear to dwindle over time. They stick to the virus in order to stop it.
Coronavirus immunity: Can you catch it twice?
Antibodies 'fall rapidly after Covid infection'
The people with hidden immunity against Covid-19
They have also discovered that a kind of immune cell, called a T-cell, attacks the cells infected with the virus. This is known as the cellular immune response and could also be key.
This study, which has not yet been peer-reviewed or published in a journal, suggests T-cells could play the more important role.
The research was carried out by the UK Coronavirus Immunology Consortium, involving the University of Birmingham, the NIHR Manchester clinical research facility and Public Health England.
SARS-CoV-2 virus
IMAGE COPYRIGHTGETTY IMAGES
image captionThere is an antibody response and a cellular response to the coronavirus
"Early results show that T-cell responses may outlast the initial antibody response, which could have a significant impact on Covid vaccine development and immunity research," said Dr Shamez Ladhani, study author and consultant epidemiologist at Public Health England.
Prof Paul Moss, from the University of Birmingham, said the study was the first in the world "to show robust cellular immunity remains at six months after infection".
This was based on samples taken from 23 male and 77 female healthcare workers who had been infected with coronavirus in March or April, and had either mild to moderate symptoms or were asymptomatic. None of them were ill enough to be admitted to hospital with Covid-19.
How close are we to a coronavirus vaccine?
Are Indians more immune to Covid-19?
The researchers say it is possible that a good T-cell response might provide people who had symptoms with more protection against being infected again.
But it could also be that asymptomatic people are simply able to fight off the virus without needing to build up a large immune .
and another snip from Wales..... What do they know that us shareholders haven't been told? it was on the welsh BBC news at 13.09pm today
First Minister Mark Drakeford says he is optimistic a “new generation of tests” giving quicker result times will soon become available in Wales.
He referred to the new coronavirus tests whilst answering a question during a press briefing about whether care home visits would be possible when the Welsh lockdown ends next Monday.
“One of the things that we do have some optimism that things will develop over the weeks ahead, is that a new generation of tests may become available, where people will be able to administer themselves and then be able to get the answers very quickly within let us say half an hour," he said.
Mr Drakeford said he had asked officials to work with the care home sector to make sure the tests when they become available were a “priority”.
He explained the test could be administered by a member of the public wanting to visit a relative “whilst they are waiting in the car, and within half an hour they would know that they had a test that was positive or negative”.
Mr Drakeford added that it offered a “different path to this very difficult dilemma”.
Good to see some oxygen being brought back into the share price, healing for a full recovery takes time, perhaps if we all take a "deep" breath we can "verge" on the side of upward momentum.
"Whats going on".... send the lyrics to Gerry, we need more PR in the best way. No 10 "knock Knock Knocking on Heavens Door", come on Gerry as the saying goes "grab the bull by the horn's" or "grab the decision maker by the 8alls", let's show the world what Deepverge are made of, this is the chance of a lifetime or the last chance of OUR lifetime.
Thought we were ahead of the game..... just on our local news now...
Covid: New breath test could detect virus in seconds
Early trials of a new test for coronavirus open up the possibility of "rapid identification" for the disease in seconds rather than hours.
Research shows breath analysis developed in Wales may be able to distinguish Covid-19 from other chest infections almost immediately.
Results published by the Lancet follow trials in Scotland and Germany.
Developers Imspex Diagnostics said its devices could be ready to use in six months - if they can secure funding.
"The potential, I think, is very exciting," said founder and chief executive Santi Dominguez.
"Being so immediate, you could see many different applications outside a traditional hospital environment.
"You could see the potential in aviation, you could see it in transportation in general, you could see it in immigration.
"You could take a quick sample, it's non-invasive, you don't need a particularly specialised person to collect those samples - and a few minutes later you get a result."
What types of Covid tests are available?
How to book a Covid test
Lockdown: The rules where you live
The latest machines were developed by Imspex at its headquarters in the Cynon Valley in south Wales.
Originally, the technology was being used to develop tests to detect illnesses such as lung cancer, and how to distinguish between bacterial and viral respiratory diseases quickly.
But as the new strain of coronavirus became a global pandemic, the firm took the decision to focus its diagnostic efforts on the emerging disease.
"We do have experience in that area, and experience in its implementation. When Covid came along, it made us divert in that direction and to contribute to the effort," added the Imspex chief.
Coronavirus swab test
IMAGE COPYRIGHTGETTY IMAGES
image captionCurrent tests involve an invasive swab - unlike this new method
Two trials have now been carried out using the firm's technology, on hospital patients in Edinburgh and in Dortmund, Germany, early in the Covid outbreak.
The study, led by Loughborough University, evolved from the university's work on its toxi-triage project to help emergency services in civil disasters.
The researchers tried to pinpoint whether the machines could tell the difference between a patient with Covid-19 or another type of chest infection.
The equipment analysed single breath samples, looking for volatile chemicals present in the expelled air that might give scientists a clue to why a patient was sick and had respiratory issues.
The tests were able to make out a "signature" for Covid in the chemicals, which was then confirmed by more traditional, and invasive, swab tests.
In 80% of cases, they were able to accurately predict if the patient had Covid-19 - distinguishing the illness from other breathing problems such as asthma or bacterial pneumonia.
https://www.bbc.co.uk/news/uk-wales-547188
This is a Covid operation, lets cut the crap and breath some new life into this share, don't get caught with your pants, the time to buy is now, no need for any disabled ramps, just sit back and let it gooooooo
Anybody got some more to squeeze out or just leave it run until the final result, anyway i'm chuff ed to be part of Deepverge , let's see what lurks at the bottom of the bowl
Chesh ... looking back and up to date with relations at Bangor , interesting to note Dr Davey Jones latest tweet "Defra UK
@DefraGovUK
·
Oct 23
The UK has made a breakthrough in using science to tackle #coronavirus.
Scientists can now use sewage to detect local outbreaks, even when people don't show symptoms.
When you read the full article it's also interesting to note that going back to June 2020 it says this, A government-led project is successfully detecting traces of coronavirus in sewerage, providing an early warning for local outbreaks across the country and sharing data with NHS Test and Trace.
The programme, which was first announced in June, has now proven that fragments of genetic material from the virus can be detected in wastewater. This can then indicate where a local community or an institution is experiencing a spike in cases.
https://www.gov.uk/government/news/sewage-signals-early-warning-of-coronavirus-outbreaks
When you look at Integumen (deepverge) for June 2020 we have this statement...AIM share code: SKIN
22 June 2020
Integumen PLC
("Integumen" or "Company")
Integumen COVID-19 MTA signed with Aptamer Group Ltd
Collaboration targets wastewater identification of local COVID-19 hotspots
Integumen has signed a Material Transfer Agreement ("MTA") with the Aptamer Group Limited ("Aptamer Group") to develop and manufacture aptamers to detect SARS-CoV-2 in wastewater. The aptamers have the potential to play a key role in the real-time identification of localised COVID-19 hotspots in wastewater, from which authorities can be alerted through Integumen's real-time alert system to prevent the spread of the disease to the wider community.
The MTA formalises Integumen's access to Aptamer Group's raw materials for coating aptamers on silicon wafer surfaces at nano-scale. Integumen will provide the Aptamer Group with access to its UK Sand Hutton manufacturing facilities, which specialises in laboratory grown human skin equivalents specifically designed to host bacteria, virus and fungi. A pilot batch of the aptamers will be tested on Integumen's SARS-CoV-2 model virus. Once initial testing is complete in two months, validation on the real SARS-CoV-2 virus will be carried out at the containment level 3 ("CL3") laboratory in the University of Aberdeen.
Upon completion of the validation study, Integumen and the Aptamer Group will enter into a longer-term supply agreement, with Integumen manufacturing and commercialising real-time pathogenic virus and bacteria detection devices through its production, sales, marketing and distribution channel partners around the world.
Also on a local basis here in Wales our news reads along with government funding........
A second waste water project is under way at Swansea University, which aims to develop a sampling and reporting device to predict the outbreak of coronavirus infections.
The programme is led by Bangor University, working with Cardiff University, Public Health Wales and Dwr Cymru Welsh Water and it has been awarded almost £500,000 of Welsh Government funding.
https://www.bbc.co.uk/news/uk-wales-54661893
Seems to be a fair amount of activity at Penn Uni
Yufan Biotech, Abound Bio Partner on HPK1-Inhibiting CAR T-Cell Therapies
Sep 16, 2020 | staff reporter
NEW YORK – Xi'an, China-based Yufan Biotechnologies and Pittsburgh-based Abound Bio announced on Wednesday that they had entered a three-year partnership to jointly develop CAR T-cell therapies directed at 10 different cancer targets.
The companies plan to improve the efficacy of CAR T-cell therapy by using CRISPR gene editing to disrupt the expression of endogenous HPK1, a gene that plays a role in T-cell exhaustion through NFkB-Blimp1 activation, in effect limiting the ability of CAR T cells to destroy cancer cells. Xuebin Liao, one of Yufan's cofounders, recently led research that demonstrated the potential for the HPK1-inhibiting approach to improve CAR T-cell therapy.
The partnership will leverage Abound Bio's expertise in identifying antibodies as cancer targets and direct Yufan's investigational HPK1-inhibited CAR T-cell platform against these targets. The two companies will share inventorship and development rights for the new technologies that emerge from the collaboration.
Currently, the safety and maximum tolerated dose of the HPK1-inhibited CAR T-cell approach is being evaluated in a Phase I trial as a treatment for relapsed or refractory CD19-positive leukemia or lymphoma. An estimated 40 patients enrolled in the trial — 20 with B-cell acute lymphoblastic leukemia and 20 with B-cell lymphoma — will receive IV injections of autologous T cells that have been engineered to target CD19 and edited with CRISPR to disrupt the expression of endogenous HPK1.